Fairmount Funds Management, Director: Dianthus Therapeutics DNTH Buy · Filed 23/09/28

Trade details

Type: Insider buy
Amount: $394,500
Shares · price: 30,000 sh · $13.15 a share
Held after: 1,903,833 sh
Stock: Dianthus Therapeutics DNTH
Person: Fairmount Funds ManagementDirector
Trade date: 23/09/26
Filed: 23/09/28
Days to filing: 2 days

4 insiders bought this week

Insiders buying this week: 4 insiders
Holding change: +1.6%

Dianthus Therapeutics trades, last 26 weeks

What else happened in Dianthus Therapeutics around then

Filed or reported within 30 days of the trade day · 23/08/27~23/10/26

Fairmount Funds Management's recent trades

Fairmount Funds ManagementDirector, 10% Stockholder
Planned saleOruka Therapeutics
Planned sale
Oruka Therapeutics
ORKA
$300M
3,553,410 sh
$300M
Filed 07/01
Traded 07/01
Fairmount Funds ManagementDirector
Planned saleSpyre Therapeutics
Planned sale
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
SellSpyre Therapeutics
Sell
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
BuyViridian Therapeutics, Inc.\DE
Buy
Viridian Therapeutics, Inc.\DE
VRDN
$20M
1,176,470 sh
$20M
Filed 05/13
Traded 05/11
Fairmount Funds ManagementDirector
BuyZenas BioPharma
Buy
Zenas BioPharma
ZBIO
$3M
150,000 sh
$3M
Filed 04/01
Traded 03/31